Last reviewed 2026-04-20 · How we verify

Panfuran (FURALAZINE)

Phase 2 active Small molecule

Panfuran (generic name: FURALAZINE) is a furalazine drug. It is currently in Phase 2 development.

Furalazine is believed to work by modulating cellular responses.

Panfuran, also known as Furalazine, is a small molecule drug in the furalazine class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating cellular responses. Furalazine is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. As a result, there is limited information available on its safety profile and efficacy. Further research is needed to fully understand the properties and potential uses of Furalazine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FURALAZINE
Drug class	furalazine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key that unlocks a specific process in the body. When this process is working properly, it helps the body function correctly. However, when it's not working right, it can lead to problems, and Furalazine may help fix that.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Panfuran CI brief — competitive landscape report
Panfuran updates RSS · CI watch RSS

Frequently asked questions about Panfuran

What is Panfuran?

Panfuran (FURALAZINE) is a furalazine drug.

How does Panfuran work?

Furalazine is believed to work by modulating cellular responses.

What is the generic name of Panfuran?

FURALAZINE is the generic (nonproprietary) name of Panfuran.

What drug class is Panfuran in?

Panfuran belongs to the furalazine class. See all furalazine drugs at /class/furalazine.

What development phase is Panfuran in?

Panfuran is in Phase 2.

Drug class: All furalazine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing